Syndax Pharmaceuticals Inc
(NAS:SNDX)
$
13.07
-0.24 (-1.8%)
Market Cap: 1.12 Bil
Enterprise Value: 710.08 Mil
PE Ratio: 0
PB Ratio: 3.04
GF Score: 32/100 Syndax Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 08:50PM GMT
Release Date Price:
$8.82
(-0.56%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP
(technical difficulty)
.com/researchdisclosures, or at the registration desk. And I'm one of our biotechnology analysts. My name is David Lebowitz, and I'd like to welcome to the stage with me from Syndax Pharmaceuticals, CEO, Briggs Morrison. Glad to have you back again.
Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director
Good to see you, David.
David Neil Lebowitz
Morgan Stanley, Research Division - VP
Before we get started, I guess let's start with Syndax from a top level discussion. What's -- can you tell me about the company itself, where you came from and what your overall mission is.
Briggs W. Morrison
Syndax Pharmaceuticals, Inc. - CEO & Director
Sure. So our overall mission is to realize a future in which people with cancer live longer and better than ever before. And our overall business strategy is to license in molecules that we think have the potential to achieve
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot